ERBB2 emerges as a new target for colorectal cancer
Eirini Pectasides1, Adam J Bass2
1Division of Hematology and Oncology, Beth Israel Deaconess Hospital, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract:
ERBB2 mutations and amplifications are present in 7% of colorectal cancers. The presence of these alterations may be a marker of resistance to anti-EGFR therapy and, more importantly, could help identify patients who would benefit from ERBB2-directed therapy.
Insights
ERBB2 alterations are found in 7% of colorectal cancers. These changes can predict resistance to anti-EGFR drugs and identify patients for ERBB2-targeted treatments.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Colorectal cancer (CRC) is a significant global health concern.
- Epidermal growth factor receptor (EGFR) targeted therapies are standard treatments for some metastatic CRCs.
- Mechanisms of resistance to anti-EGFR therapy are critical to understand for improving patient outcomes.
Purpose of the Study:
- To investigate the role of ERBB2 (also known as HER2) mutations and amplifications in colorectal cancer.
- To determine if ERBB2 alterations are associated with resistance to anti-EGFR therapy.
- To explore the potential of ERBB2 as a predictive biomarker for ERBB2-directed therapies in CRC.
Main Methods:
- Analysis of ERBB2 gene status (mutations and amplifications) in a cohort of colorectal cancer patients.
- Correlation of ERBB2 alterations with clinical response to anti-EGFR therapy.
- Evaluation of ERBB2 alterations as potential targets for novel therapeutic strategies.
Main Results:
- ERBB2 mutations and amplifications were identified in approximately 7% of the studied colorectal cancer cases.
- The presence of ERBB2 alterations may indicate a poorer response to standard anti-EGFR therapies.
- ERBB2 alterations represent a potential actionable target for specific patient subgroups.
Conclusions:
- ERBB2 alterations are an emerging factor in colorectal cancer biology.
- Identifying ERBB2 alterations can help stratify patients for anti-EGFR therapy.
- ERBB2-directed therapies may offer a new treatment avenue for a subset of colorectal cancer patients with these specific genetic changes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:38Mitogens and the Cell Cycle
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The Retinoblastoma Gene
02:56Treatment Resistent Cancers